Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.16 USD
-0.02 (-1.69%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $1.15 -0.01 (-0.86%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Biorestorative Therapies, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 19 | 26 | 3 | 9 |
Income After Depreciation & Amortization | -15 | -19 | -26 | -3 | -8 |
Non-Operating Income | 0 | 0 | -16 | -8 | -5 |
Interest Expense | -1 | 0 | 2 | 0 | 1 |
Pretax Income | -14 | -18 | -44 | -11 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -18 | -44 | -11 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -18 | -44 | -11 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -19 | -25 | -1 | -5 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 1 | 4 |
Income After Depreciation & Amortization | -15 | -19 | -26 | -3 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.22 | 3.62 | 1.19 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.42 | -5.11 | -37.30 | NA | NA |
Diluted Net EPS (GAAP) | -3.42 | -5.11 | -37.30 | -33.33 | -2,200.00 |
Fiscal Year end for Biorestorative Therapies, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.02 | 0.03 | 0.06 | 0.03 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.02 | 0.03 | 0.06 | 0.03 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.24 | 3.13 | 3.18 | 5.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.22 | -3.10 | -3.12 | -5.78 |
Non-Operating Income | NA | 0.02 | 0.12 | 0.04 | 0.08 |
Interest Expense | NA | -0.38 | -0.06 | -0.10 | -0.02 |
Pretax Income | NA | -2.83 | -2.93 | -2.98 | -5.68 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.83 | -2.93 | -2.98 | -5.68 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.83 | -2.93 | -2.98 | -5.68 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 4.22 | 4.57 | 3.89 | 3.72 |
Diluted EPS Before Non-Recurring Items | NA | -0.57 | -0.64 | -0.77 | -1.53 |
Diluted Net EPS (GAAP) | NA | -0.48 | -0.64 | -0.77 | -1.53 |